Fortrea Holdings Inc.
Fortrea Holdings Inc.
Your view on FTRE
Overview
What the company does, where it operates, and who runs it.
About Fortrea Holdings Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Anshul Thakral
- Headquarters
- 8 Moore Drive, Durham, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Anshul Thakral
- Headquarters
- 8 Moore Drive, Durham, NC, US
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services.
The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process.
The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services.
The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Fortrea Holdings Inc., and the rating behind it. FTRE last traded at $17.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Fortrea Holdings Inc.. Starting points for Fortrea Holdings Inc.: EPS -$0.90, beta 1.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Fortrea Holdings Inc.. Fortrea Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Fortrea Holdings Inc.. Trailing twelve-month EPS for Fortrea Holdings Inc. stands at -$0.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Fortrea Holdings Inc.. Fortrea Holdings Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Fortrea Holdings Inc. valued side by side against its closest peers. Fortrea Holdings Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Fortrea Holdings Inc., and how their positions are changing. At a $1.64B market value, institutional positions materially move Fortrea Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Fortrea Holdings Inc. executives and directors. Shares of Fortrea Holdings Inc. have traded between $3.97 and $25.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Fortrea Holdings Inc.. Fortrea Holdings Inc. is a $1.64B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Fortrea Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Fortrea Holdings Inc.. Coverage tracks Fortrea Holdings Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.